Impact of palivizumab immunization in controlling respiratory syncytial virus infections among preterm neonates after hospital discharge in the tropics

Kok Pim Kua, Nadia K. Qureshi, Kon Ken Wong, David Bin Chia Wu, Shaun Wen Huey Lee, Fook Choe Cheah

Research output: Contribution to journalArticleResearch

1 Citation (Scopus)


Background: Preterm neonates are at a greater risk of hospitalization for respiratory syncytial virus (RSV) infection and have significantly worse hospital outcomes compared with full-term neonates. Aim: To determine the incidence of RSV respiratory tract infections (RTIs) among preterm neonates aged < 29 weeks and/or 1000 g birth weight under a controlled palivizumab immunization program Materials and Methods: This was a prospective, observational cohort, single-center study. Preterm neonates, with or without palivizumab immunization, admitted to the NICU were monitored for 12 months after hospital discharge for RTI symptoms using a standard proforma through telephonic interview and further verification of hospital records. The presence of RSV was confirmed by real-time reverse transcription polymerase chain reaction on available nasal swab samples. Results: A total of 196 neonates were enrolled, of whom 55 (28%) neonates were palivizumab immunized (PVI) and 141 (72%) were nonpalivizumab immunized (NPV). The mean gestation of PVI neonates was 28.7 ± 2.2 weeks and their mean birth weight was 1.14 ± 0.41 kg; 43.6% of these PVI neonates had bronchopul-monary dysplasia. Overall, PVI neonates tested lower for RSV throughout the study period compared with NPV neonates. The number of neonates who required rehospitalization was more.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
Issue number1
Publication statusPublished - Apr 2019

Cite this